

10/755,545

Sequence alignment B

SEQ ID NO:2

AA01098

ID AA01098 standard; protein; 263 AA.

XX

XX

AC AA01098;

XX

DT 15-JUN-2007 (revised)

DT 11-JUN-1999 (first entry)

XX

DE Human follistatin-3 protein sequence.

XX

KW Follistatin-3; human; cancer; cellular growth disorder; liver cirrhosis;

KW differentiation disorder; reproductive system disorder; male sterility;

KW activin-induced differentiation inhibitor; gonadotroph adenoma; hepatoma;

KW osteosarcoma; idiopathic pulmonary fibrosis; pulmonary fibrosis; tumour;

KW fibrotic disorder; osteoarthritis; haematopoiesis; infectious disease;

KW sepsis; cancer; silicosis; sarcoidosis; endotoxic shock; therapy;

KW BOND_PC; follistatin-like 3 glycoprotein; follistatin-related protein;

KW follistatin-like 3 glycoprotein [Homo sapiens]; FSTL3; FLRG; FSRP;

KW follistatin-like 3 glycoprotein precursor;

KW follistatin-like 3 glycoprotein;

KW follistatin-like 3 glycoprotein precursor [Homo sapiens];

KW follistatin-like 3 (secreted glycoprotein), isoform CRA_A;

KW follistatin-like 3 (secreted glycoprotein), isoform CRA_a [Homo sapiens];

KW FSTL3 [Homo sapiens]; follistatin-like 3 (secreted glycoprotein);

KW Follistatin-like 3 (secreted glycoprotein) [Homo sapiens];

KW follistatin-related protein FLRG;

KW follistatin-related protein FLRG [Homo sapiens]; G05615; G017106;

KW G030514; G048185; G08151.

XX

OS Homo sapiens.

XX

PN W09910364-A1.

XX

PD 04-MAR-1999.

XX

PF 27-AUG-1998; 98WO-US017710.

XX

PR 29-AUG-1997; 97US-0056248P.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Ruben SM, Duan R;

XX

DR WPI; 1999-204646/17.

DR N-PSDB; AAX28124.

DR PC:NCBI; gi5031701.

DR PC:SWISSPROT; 095633.

XX

PT New follistatin-3 polypeptides and nucleic acids - used to develop

PT products for treating e.g. cancers, male sterility, wound healing,

PT fibrotic disorders, angiogenesis and autoimmune, inflammatory and

PT infective diseases.

XX

PS Claim 18; Fig 1; 109pp; English.

XX

CC This sequence is the follistatin-3 (FS3) protein of the invention. The

CC products can be used to treat cancers and other cellular growth and

CC differentiation disorders as well as disorders of the reproductive

CC system. FS3 can be used or to treat male sterility. FS3 may also be used

CC to inhibit the activin-induced differentiation of follicular granulosa

CC cells. FS3 may be used therapeutically to regulate autoocrine endothelial

CC cell activity and, as a result, induce angiogenesis. Treatment to

CC increase the expression or the presence of FS3 may be used to inhibit the

CC progression of gonadotroph adenomas, osteosarcomas, hepatomas, and other

CC tumours and cancers. FS3 may also be used to treat other fibrotic

CC disorders including liver cirrhosis, osteoarthritis and pulmonary

CC fibrosis. It may also be used to regulate haematopoiesis, and to treat

CC sepsis. Antagonists of FS3 may be used to treat a deficiency in FSH,
 CC oestrogen and other hormones, to prevent or inhibit or reduce the
 CC production of spermatozoa, to modulate gonadal androgen biosynthesis. FS3
 CC antagonists may also be used to treat infectious diseases including
 CC silicosis, sarcoidosis, idiopathic pulmonary fibrosis by altering the
 CC activation state of mononuclear phagocytes, to treat idiopathic hyper-
 CC eosinophilic syndrome by preventing eosinophil production and activation.
 CC Endotoxic shock may also be treated by FS3 antagonists by preventing the
 CC activation of macrophages

CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.

XX

SQ Sequence 263 AA;

Query Match 100.0%; Score 1492; DB 2; Length 263;
 Best Local Similarity 100.0%; Pred. No. 3.3e-104;
 Matches 263; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MRPGAPGLMPLPWGALAWAVGFVSSMSGNPNAPGGVCMWQQGQBATCSVLVQTDVITRAE	60
Db	1	MRPGAPGLMPLPWGALAWAVGFVSSMSGNPNAPGGVCMWQQGQBATCSVLVQTDVITRAE	60
Qy	61	CCASGNIDTAWSNLTHPGNKINLLGFLGLVHCLPCKDSCDGVCEGPGKACRMIGGRPRCE	120
Db	61	CCASGNIDTAWSNLTHPGNKINLLGFLGLVHCLPCKDSCDGVCEGPGKACRMIGGRPRCE	120
Qy	121	CAPDCSGLPARLQVCGSDGATYRDECELRAARCRGHPDLVSMYRGRCKRSCEHVVCPRPQ	180
Db	121	CAPDCSGLPARLQVCGSDGATYRDECELRAARCRGHPDLVSMYRGRCKRSCEHVVCPRPQ	180
Qy	181	SCVVDQTGSAHCVCRAAPCPVPSSPGQELCGNNNVITYISSCHMRQATCFLGRSIGVRHA	240
Db	181	SCVVDQTGSAHCVCRAAPCPVPSSPGQELCGNNNVITYISSCHMRQATCFLGRSIGVRHA	240
Qy	241	GSCAGTPEEPPGGESAEEEEENFV 263	
Db	241	GSCAGTPEEPPGGESAEEEEENFV 263	